DT-168

Phase 2Small molecule

DDesign Therapeutics, Inc.

DT-168 is one of 4 small molecule programs targeting Fuchs endothelial corneal dystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fuchs Endothelial Corneal DystrophyActive, not recruiting

Fuchs Endothelial Corneal DystrophyPhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Fuchs Endothelial Corneal Dystrophy

#DrugCompanyPhaseTrials

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—2

Ripasudil

KKowa Research Institute, Inc.

Phase 3

2 3

DT-168

DDesign Therapeutics, Inc.

Phase 2

1 4

Artificial Tear Substitute

UUniversity Hospital Dubrava

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Fuchs Endothelial Corneal Dystrophy

NCT07024693

Clinical

Trials by Indication[1]

Fuchs endothelial corneal dystrophy1 trial

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Recruiting·DDesign Therapeutics, Inc.·Phase 2·NCT07024693·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DT-168. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DT-168 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DT-168. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Design Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDesign Therapeutics, Inc.

DT-168

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Fuchs endothelial corneal dystrophy1 trial

References

Drug Info

Quick Facts

Related News